Cullinan Therapeutics Mengumumkan Data Awal Positif dari Studi Fase 2b REZILIENT1 Zipalertinib Oleh Investing.com
Cullinan Therapeutics, Inc. announced positive initial data in patients receiving zipalertinib after prior treatment with amivantamab in its Phase 2b REZILIENT1 clinical trial. The objective response rate was 39% with a manageable safety profile. Zipalertinib demonstrated promising efficacy in patients who had progressed after prior treatment and had received amivantamab. The drug has received Breakthrough … Baca Selengkapnya